Anzeige
Mehr »
Login
Donnerstag, 16.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EACA | ISIN: SE0001337213 | Ticker-Symbol: 516
Frankfurt
25.10.24
09:18 Uhr
0,061 Euro
0,000
0,00 %
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
AURIANT MINING AB Chart 1 Jahr
5-Tage-Chart
AURIANT MINING AB 5-Tage-Chart
GlobeNewswire (Europe)
145 Leser
Artikel bewerten:
(0)

Bulletin from the Annual General Meeting of Auriant Mining AB (publ) held on 14 May 2024

Finanznachrichten News

Auriant Mining AB (publ) held its Annual General Meeting on Tuesday, 14 May 2024.

The main resolutions passed at the meeting were as follows. More detailed information about the contents of all resolutions may be obtained from the complete notice to the Annual General Meeting and the complete proposals. The notice and the complete proposals are available on the company's website: www.auriant.com.

Adoption of balance sheets and profit and loss accounts

It was resolved at the meeting to adopt the profit and loss account and balance sheet, as well as the consolidated profit and loss account and consolidated balance sheet for the financial year 2023.

Allocation regarding the company's result

In accordance with the board of directors' and the CEO's proposal, it was resolved at the meeting that the year's result shall be carried forward.

Discharge from liability

The meeting discharged the board members and the CEO from liability for the financial year 2023.

Board and auditors

In accordance with the nomination committee's proposal, it was resolved at the meeting that the board shall consist of four (4) members without any deputy board member, and that the number of auditors shall be one (1) without any deputy auditor.

Peter Daresbury, Thor Åhlgren, Preston Haskell and Jukka Pitkäjärvi were re-elected as board members for the period until the end of the next annual general meeting. Peter Daresbury was re-elected as chairman of the board.

The authorised public accountant Johan Kaijser was re-elected as the company's auditor for the period until the end of the next Annual General Meeting.

It was resolved at the meeting that the remuneration to the chairman of the board shall be SEK 440,000 and SEK 275,000 to each of the other board members. If any committee is established by the board of directors, remuneration in the amount of SEK 27,500 per annum shall be paid to each member of the committee for participation in it. The maximum amount that may be paid to the board, including remuneration for committee work, amounts to SEK 1,512,500.

It was resolved at the meeting that fees would be paid to the auditor in accordance with agreement between the company and the auditor.

Nomination committee

It was resolved at the meeting to adopt the principles for the appointment of the nomination committee and the instruction for the nomination committee in accordance with the nomination committee's proposal.

Authorisation for the board of directors to resolve upon issue of shares, warrants and/or convertibles

The meeting authorised the board to resolve - at one or several occasions and for the time period until the next annual general meeting - to increase the company's share capital by new issues of shares, warrants and/or convertibles. The number of shares that may be issued and the number of shares that shall be possible to convert/subscribe for may amount to a number of shares resulting in a dilution of not more than 20 percent of the number of shares outstanding at the time of this notice of the Annual General Meeting, after full exercise of the hereby proposed authorisation.

New issues of shares, warrants and/or convertibles may be made with or without deviation from the shareholders' preferential rights and with or without provisions for contribution in kind, set-off or other conditions. Pursuant to Chapter 16 of the Swedish Companies Act, the board of directors may not by virtue of this authorisation resolve on issues to board members in group companies, employees, etc. The purpose of the authorisation is to increase the financial flexibility of the company and the acting scope of the board. Should the board of directors resolve on an issue with deviation from the shareholder's preferential rights, the reason shall be to enable the company to finance the operations in a fast and efficient way, acquire companies, businesses or parts thereof, or to broaden the ownership of the company. Upon such deviation from the shareholders' preferential rights, the new issue shall be made at market terms and conditions.

For more information, please contact:

Danilo Lange, CEO
Tel: +7 495 109 02 82
e-mail: d.lange@auriant.com

Company name: Auriant Mining AB (publ)
Short name: AUR
ISIN-code: SE0001337213

Website: www.auriant.com

Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Russia, primarily in the Republic of Tyva, Zabaikalye and the Republic of Khakassia. The company has currently four assets, including two operating mines (Tardan and Alluvial at Staroverinskaya), one early stage exploration asset and one development asset.

Since July 19, 2010, Auriant Mining's shares are traded on Nasdaq First North Premier Growth Market under the short name AUR. For more information, please visit www.auriant.com. G&W Fondkommission is Certified Adviser to Auriant, for more information please visit www.gwkapital.se.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.